Elisa Agostinetto: Do patients with ER-low (1-10%) tumors benefit from adjuvant ET?
Hope Rugo, Professor of Medicine and Director of Breast Oncology and Clinical Trials Education at the University of California at San Francisco, shared a post by Elisa Agostinetto on X, adding:
“Would caution major caution in interpreting this data. This is an extremely heterogeneous disease. ER<5% and most <10% are unlikely to benefit from ET. Argues for neoadjuvant chemotherapy in this high-risk setting. PCR had no benefit. Careful eval of heterogeneity – not a median.”
Quoting Elisa Agostinetto’s post:
“Do patients with ER-low (1-10%) tumors benefit from adjuvant ET?
At ASCO24 an analysis of >10,000 ER-low tumors shows that ET omission was associated with low overall survival, suggesting that adjuvant ET should be recommended to these patients as standard of care.”
Sources: Hope Rugo/X and Elisa Agostinetto/X
Dr. Elisa Agostinetto is a medical oncologist, specializing in breast cancer research. Trained in Milan, Italy, she currently conducts advanced research at Institut Jules Bordet – Université Libre de Bruxelles in Brussels, Belgium. Actively engaged in professional societies like ESMO, ASCO, and BSMO, she also contributes as a young investigator in the EORTC Breast Cancer Working Group and as a Committee member of the Young Cancer Professionals within the European Cancer Organization.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023